Miscellaneous immune disorders:
Indications for: FIRDAPSE
Lambert-Eaton myasthenic syndrome (LEMS) in patients aged ≥6yrs.
Adults and Children:
<6yrs: not established. ≥6yrs (<45kg): Initially 5–15mg daily in 3–4 divided doses; may increase by 2.5mg every 3 or 4 days (max single dose: 10mg; max total: 40mg/day). ≥6yrs (≥45kg): Initially 15–30mg daily in 3–4 divided doses; may increase by 5mg every 3 or 4 days (max single dose: 20mg; max total: 80mg/day). Hepatic or renal impairment (CrCl 15–90mL/min), NAT2 poor metabolizers: 15mg daily (for patients ≥45kg) and 5mg daily (for patients <45kg) in 3 divided doses. Patients who require dosage <5mg increments, have difficulty swallowing, or require feeding tubes: may prepare a 1mg/mL oral suspension; see full labeling.
FIRDAPSE Contraindications:
History of seizures.
FIRDAPSE Warnings/Precautions:
Consider dose reduction or discontinuation if seizure occurs. Discontinue and treat if anaphylaxis occurs. Hepatic or renal impairment: monitor; adjust dose or discontinue as needed. N-acetyltransferase 2 (NAT2) poor metabolizers. Elderly. Pregnancy. Nursing mothers.
FIRDAPSE Classification:
Potassium channel blocker.
FIRDAPSE Interactions:
Concomitant drugs that lower seizure threshold may increase seizure risk. Additive effects when concomitant drugs with cholinergic effects (eg, direct or indirect cholinesterase inhibitors).
Adverse Reactions:
Paresthesia, upper RTI, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, muscle spasms; seizures, hypersensitivity.
Generic Drug Availability:
NO
How Supplied:
Tabs—60, 240; Blister packs—10, 120
